Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?: Miniperspective

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583 · see citing works

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244 · see citing works

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works

SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works

Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · see citing works

The amyloid state and its association with protein misfolding diseases.

Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382 · see citing works

Inflammation as a central mechanism in Alzheimer's disease

Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · see citing works

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease

Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · see citing works

GSK-3: tricks of the trade for a multi-tasking kinase

Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · see citing works

Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development

Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965 · see citing works

Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease

Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954 · see citing works

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768 · see citing works

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

Ittner, L. M., & Götz, J. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2967 · Cited by 1,357 · see citing works

Designed Multiple Ligands. An Emerging Drug Discovery Paradigm

Morphy, R., & Ranković, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,237 · see citing works

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

Alzheimer's disease: strategies for disease modification

Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works

Kinase inhibitors: the road ahead

Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009 · see citing works

Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments

Alonso, A. D. C., Zaidi, T., Novák, M., Grundke, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 968 · see citing works

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease

Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · see citing works

Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules

Alonso, A. D. C., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0796-783 · Cited by 859 · see citing works

Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease

Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831 · see citing works

GSK3 signalling in neural development

Hur, E., & Zhou, F. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2870 · Cited by 828 · see citing works

The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives

Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · see citing works

Cu(II) Potentiation of Alzheimer Aβ Neurotoxicity

Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J. D. A., Hanson, G. R., Stokes, K. C., Leopold, M., Multhaup, G., Goldstein, L. E., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37111 · Cited by 762 · see citing works

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy

Sengupta, U., Nilson, A. N., & Kayed, R. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.035 · Cited by 740 · see citing works

Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase

Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737 · see citing works

A perspective on multi‐target drug discovery and design for complex diseases

Ramsay, R. R., Popović-Nikolić, M. R., Nikolic, K. M., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 730 · see citing works

History and progress of hypotheses and clinical trials for Alzheimer’s disease

Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723 · see citing works

A Common Phosphate Binding Site Explains the Unique Substrate Specificity of GSK3 and Its Inactivation by Phosphorylation

Frame, S., Cohen, P., & Biondi, R. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00253-2 · Cited by 703 · see citing works

Alzheimer's disease drug development pipeline: 2018

Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · see citing works

Glycogen synthase kinase-3 signaling in Alzheimer's disease

Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 624 · see citing works

Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau.

Matsuo, E. S., Shin, R., Billingsley, M., de Voorde, A. V., O'Connor, M., Trojanowski, J., & Lee, V. (1994) · Neuron · doi:10.1016/0896-6273(94)90264-x · Cited by 588 · see citing works

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update

Roskoski, R. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 566 · see citing works

The road to restoring neural circuits for the treatment of Alzheimer's disease

Canter, R. G., Penney, J., & Tsai, L.-H. (2016) · Nature · doi:10.1038/nature20412 · Cited by 565 · see citing works

Phosphorylation that Detaches Tau Protein from Microtubules (Ser262, Ser214) Also Protects It against Aggregation into Alzheimer Paired Helical Filaments

Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., & Mandelkow, E.-M. (1999) · Biochemistry · doi:10.1021/bi981874p · Cited by 564 · see citing works

Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418

Bhat, R. V., Xue, Y., von Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 557 · see citing works

Alzheimer’s disease drug development pipeline: 2020

Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557 · see citing works

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds

Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498 · see citing works

Polypharmacology – Foe or Friend?

Peters, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 477 · see citing works

Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization

Gregory, M. A., Qi, Y., & Hann, S. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310722200 · Cited by 476 · see citing works

First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease

Martı́nez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 457 · see citing works

Current understanding of metal ions in the pathogenesis of Alzheimer’s disease

Wang, L., Yin, Y.-L., Liu, X.-Z., Shen, P., Zheng, Y.-G., Lan, X.-R., Lu, C.-B., & Wang, J.-Z. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00189-z · Cited by 454 · see citing works

GSK-3β, a pivotal kinase in Alzheimer disease

Llorens-Marítin, M., Jurado, J., Hernández, F., & Ávila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451 · see citing works

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140665 · Cited by 445 · see citing works

Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes

Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442 · see citing works

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440 · see citing works

CREB DNA binding activity is inhibited by glycogen synthase kinase‐3β and facilitated by lithium

Grimes, C. A., & Jope, R. S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00495.x · Cited by 437 · see citing works

Increased NF-Κb Signalling Up-Regulates BACE1 Expression and its Therapeutic Potential in Alzheimer's Disease

Chen, C.-H., Zhou, W., Liu, S., Deng, Y., Cai, F., Tone, M., Tone, Y., Tong, Y., & Song, W. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000149 · Cited by 433 · see citing works

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L. M., Wang, Y., Peng, B., Abrey, L. E., Raizer, J. J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 424 · see citing works

GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder

Valvezan, A. J., & Klein, P. S. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00001 · Cited by 384 · see citing works

Paullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25

Leost, M., Schultz, C., Link, A., Wu, Y., Biernat, J., Mandelkow, E., Bibb, J. A., Snyder, G. L., Greengard, P., Zaharevitz, D. W., et al. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01673.x · Cited by 378 · see citing works

α-synuclein in the pathophysiology of Alzheimer’s disease

Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works

Phosphorylation of Tau at Both Thr 231 and Ser 262 Is Required for Maximal Inhibition of Its Binding to Microtubules

Sengupta, A., Kabat, J., Novak, M., Wu, Q., Grundke-Iqbal, I., & Iqbal, K. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0813 · Cited by 363 · see citing works

The amyloid hypothesis on trial

Makin, S. (2018) · Nature · doi:10.1038/d41586-018-05719-4 · Cited by 360 · see citing works

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

Eldar-Finkelman, H., & Martı́nez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 356 · see citing works

Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models

Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352 · see citing works

New Insights Into the Pathogenesis of Alzheimer's Disease

Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 349 · see citing works

Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation

Hooper, C., Markevich, V. A., Plattner, F., Killick, R., Schofield, E., Engel, T., Hernández, F., Anderton, B. H., Rosenblum, K., Bliss, T., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05245.x · Cited by 345 · see citing works

Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer’s Disease and Related Neurodegenerative Disorders

Forlenza, O. V., de Paula, V. D. J. R., & Diniz, B. S. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000309 · Cited by 333 · see citing works

Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · see citing works

Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors

Bertrand, J. A., Thieffine, S., Vulpetti, A., Cristiani, C., Valsasina, B., Knapp, S., Kalisz, H. M., & Flocco, M. M. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.031 · Cited by 325 · see citing works

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease

Lee, J. K., & Kim, N. (2017) · Molecules · doi:10.3390/molecules22081287 · Cited by 323 · see citing works

A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320 · see citing works

Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?

Naini, S. M. A., & Soussi‐Yanicostas, N. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/151979 · Cited by 318 · see citing works

Role of metal dyshomeostasis in Alzheimer's disease

Bonda, D., Lee, H., Blair, J. A., Zhu, X., Perry, G. L., & Smith, M. A. (2011) · Metallomics · doi:10.1039/c0mt00074d · Cited by 316 · see citing works

Tau pathophysiology in neurodegeneration: a tangled issue

Spires‐Jones, T. L., Stoothoff, W. H., de Calignon, A., Jones, P., & Hyman, B. T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.11.007 · Cited by 316 · see citing works

α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities

Alam, P., Bousset, L., Melki, R., & Otzen, D. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14808 · Cited by 305 · see citing works

Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice

Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300 · see citing works

Targeting protein kinases in central nervous system disorders

Chico, L. K., Eldik, L. J. V., & Watterson, D. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2999 · Cited by 292 · see citing works

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells · doi:10.3390/cells9051110 · Cited by 284 · see citing works

Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability

Alonso, A. D., Cohen, L. S., Corbo, C., Morozova, V., ElIdrissi, A., Phillips, G., & Kleiman, F. E. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00338 · Cited by 278 · see citing works

Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux

Dai, H. I., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 274 · see citing works

A Conformation‐ and Phosphorylation‐Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease

Jicha, G. A., Lane, E., Vincent, I. J., Ötvös, L., Hoffmann, R., & Davies, P. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052087.x · Cited by 264 · see citing works

Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges

Morphy, R., & Ranković, Z. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315594 · Cited by 262 · see citing works

Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling

Magdesian, M. H., Carvalho, M., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., Garcia-Abreu, J., & Ferreira, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707108200 · Cited by 251 · see citing works

Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease

Rajasekhar, K., Chakrabarti, M., & Govindaraju, T. (2015) · Chemical Communications · doi:10.1039/c5cc05264e · Cited by 241 · see citing works

Selectivity and therapeutic inhibition of kinases: to be or not to be?

Ghoreschi, K., Laurence, A. D. J., & O’Shea, J. J. (2009) · Nature Immunology · doi:10.1038/ni.1701 · Cited by 241 · see citing works

Calcium signaling in Alzheimer's disease & therapies

Tong, B. C., Wu, A. J., Li, M., & Cheung, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 235 · see citing works

Soluble forms of tau are toxic in Alzheimer's disease

Kopeikina, K., Hyman, B., & Spires-Jones, T. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0032-y · Cited by 232 · see citing works

Emerging roles of <scp>ER</scp> stress in the etiology and pathogenesis of Alzheimer's disease

Gerakis, Y., & Hetz, C. (2018) · The FEBS Journal · doi:10.1111/febs.14332 · Cited by 226 · see citing works

Multi-target design strategies for the improved treatment of Alzheimer's disease

Zhang, P., Xu, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.020 · Cited by 218 · see citing works

Targeting HDACs: A Promising Therapy for Alzheimer's Disease

Xu, K., Dai, X., Huang, H., & Jiang, Z.-F. (2011) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2011/143269 · Cited by 206 · see citing works

Regulation of protein stability by GSK3 mediated phosphorylation

Xu, C. B., Kim, N., & Gumbiner, B. M. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10111 · Cited by 205 · see citing works

Glycogen Synthase Kinase 3β Functions To Specify Gene-Specific, NF-κB-Dependent Transcription

Steinbrecher, K. A., Wilson, W., Cogswell, P. C., & Baldwin, A. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.19.8444-8455.2005 · Cited by 205 · see citing works

Clinical use of lithium salts: guide for users and prescribers

for the International Group for Studies of Lithium (IGSLi), Tondo, L., Alda, M., Bauer, M., Bergink, V., Grof, P., Hájek, T., Lewitzka, U., Licht, R. W., Manchia, M., et al. (2019) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0151-2 · Cited by 205 · see citing works

Fragments, network biology and designing multiple ligands

Morphy, R., & Ranković, Z. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204 · see citing works

Protein-protein interaction modulators: advances, successes and remaining challenges

Mabonga, L., & Kappo, A. P. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00570-x · Cited by 196 · see citing works

Tau protein, the paired helical filament and Alzheimer's disease

Goedert, M., Klug, A., & Crowther, R. A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s323 · Cited by 195 · see citing works

The Physicochemical Challenges of Designing Multiple Ligands

Morphy, R., & Ranković, Z. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603015 · Cited by 194 · see citing works

Sodium Oligomannate: First Approval

Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01268-1 · Cited by 187 · see citing works

Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimer’s Disease

Nunes, M. A., Viel, T. A., & Buck, H. S. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310010014 · Cited by 183 · see citing works

Inhibition of GSK3 by Wnt signalling – two contrasting models

Metcalfe, C., & Bienz, M. (2011) · Journal of Cell Science · doi:10.1242/jcs.091991 · Cited by 181 · see citing works

New Promise and Opportunities for Allosteric Kinase Inhibitors

Lu, X., Smaill, J. B., & Ding, K. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914525 · Cited by 170 · see citing works

GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration

Salcedo‐Tello, P., Ortiz‐Matamoros, A., & Arias, C. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/189728 · Cited by 163 · see citing works

Targeting Fyn Kinase in Alzheimer’s Disease

Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162 · see citing works

GSK-3β at the Intersection of Neuronal Plasticity and Neurodegeneration

Jaworski, T., Banach, E., & Gralec, K. (2019) · Neural Plasticity · doi:10.1155/2019/4209475 · Cited by 161 · see citing works

Alzheimer-Related τ-Pathology in the Perforant Path Target Zone and in the Hippocampal Stratum Oriens and Radiatum Correlates with Onset and Degree of Dementia

Thal, D. R., Holzer, M., Rüb, U., Waldmann, G., Günzel, S., Zedlick, D., & Schober, R. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7380 · Cited by 160 · see citing works

Rhodanine‐Based Tau Aggregation Inhibitors in Cell Models of Tauopathy

Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E., Mandelkow�, E., & Waldmann, H. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200704051 · Cited by 158 · see citing works

Glycogen Synthase Kinase 3β Negatively Regulates Both DNA-binding and Transcriptional Activities of Heat Shock Factor 1

Xavier, I. J., Mercier, P. A., McLoughlin, C., Ali, A., Woodgett, J. R., & Ovsenek, N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002169200 · Cited by 155 · see citing works

GSK3 and Alzheimer’s disease: facts and fiction…

Kremer, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00017 · Cited by 155 · see citing works

GSK‐3: A key player in neurodegeneration and memory

Giese, K.-P. (2009) · IUBMB Life · doi:10.1002/iub.187 · Cited by 150 · see citing works

Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer’s Disease

Cristóvão, J. S., Santos, R., & Gomes, C. M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9812178 · Cited by 146 · see citing works

Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models

Kramer, T., Schmidt, B., & Monte, F. L. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/381029 · Cited by 139 · see citing works

Intracellular Calcium Dysregulation: Implications for Alzheimer’s Disease

Magi, S., Castaldo, P., Macrì, M. L., Maiolino, M., Matteucci, A., Bastioli, G., Gratteri, S., Amoroso, S., & Lariccia, V. (2016) · BioMed Research International · doi:10.1155/2016/6701324 · Cited by 137 · see citing works

BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer’s Disease

Prati, F., Bottegoni, G., Bolognesi, M. L., & Cavalli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00393 · Cited by 132 · see citing works

Harnessing Polypharmacology with Medicinal Chemistry

Bolognesi, M. L. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00039 · Cited by 129 · see citing works

Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core

Sivaprakasam, P., Han, X., Civiello, R. L., Jacutin-Porte, S., Kish, K., Pokross, M. E., Lewis, H. A., Ahmed, N., Szapiel, N., Newitt, J. A., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.046 · Cited by 128 · see citing works

Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors

Prati, F., De Simone, A., Bisignano, P., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Perez, D. I., Andrisano, V., Perez‐Castillo, A., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410456 · Cited by 128 · see citing works

Glycogen Synthase Kinase 3 Regulates N-Methyl-d-aspartate Receptor Channel Trafficking and Function in Cortical Neurons

Chen, P., Gu, Z., Liu, W., & Yan, Z. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.034942 · Cited by 128 · see citing works

Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies

Medina, M., Garrido, J. J., & Wandosell, F. G. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00024 · Cited by 124 · see citing works

Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery

Jiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00463 · Cited by 122 · see citing works

Rho‐associated protein kinase 1 (<scp>ROCK</scp>1) is increased in Alzheimer's disease and <scp>ROCK</scp>1 depletion reduces amyloid‐β levels in brain

Henderson, B. W., Gentry, E. G., Rush, T., Troncoso, J. C., Thambisetty, M., Montine, T. J., & Herskowitz, J. H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13688 · Cited by 120 · see citing works

Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease

Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 116 · see citing works

GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia

Green, H. F., & Nolan, Y. M. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.07.003 · Cited by 115 · see citing works

GSK3β Activity Modifies the Localization and Function of Presenilin 1

Uemura, K., Kuzuya, A., Shimozono, Y., Aoyagi, N., Andō, K., Shimohama, S., & Kinoshita, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610708200 · Cited by 114 · see citing works

Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors

Gandini, A., Bartolini, M., Tedesco, D., Martínez‐González, L., Roca, C., Campillo, N. E., Zaldívar-Díez, J., Pérez, C., Zuccheri, G., Miti, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00610 · Cited by 112 · see citing works

Present Algorithms and Future Treatments for Alzheimer’s Disease

Grossberg, G. T., Tong, G., Burke, A. D., & Tariot, P. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180903 · Cited by 109 · see citing works

Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities

Palomo, V., Soteras, I., Pérez, D. I., Pérez, C., Gil, C., Campillo, N. E., & Martı́nez, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200996g · Cited by 108 · see citing works

Highly Potent and Specific GSK‐3β Inhibitors That Block Tau Phosphorylation and Decrease α‐Synuclein Protein Expression in a Cellular Model of Parkinson's Disease

Kozikowski, A. P., Gaisina, I. N., Petukhov, P. A., Sridhar, J., King, L. T., Blond, S. Y., Duka, T., Rusnak, M., & Sidhu, A. (2006) · ChemMedChem · doi:10.1002/cmdc.200500039 · Cited by 103 · see citing works

Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia

Wagner, F. F., Benajiba, L., Campbell, A. J., Weïwer, M., Sacher, J. R., Gale, J. P., Ross, L. S., Puissant, A., Alexe, G., Conway, A. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8460 · Cited by 100 · see citing works

TIA1 regulates the generation and response to toxic tau oligomers

Jiang, L., Ash, P. E. A., Maziuk, B. F., Ballance, H. I., Boudeau, S., Abdullatif, A. A., Orlando, M., Petrucelli, L., Ikezu, T., & Wolozin, B. L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1937-5 · Cited by 99 · see citing works

Age-related changes in glycogen synthase kinase 3β (GSK3β) immunoreactivity in the central nervous system of rats

Lee, S. J., Chung, Y. H., Joo, K. M., Lim, H. C., Jeon, G. S., Kim, D., Lee, W. B., Kim, Y. S., & Ik, C. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.09.026 · Cited by 96 · see citing works

New Insights in Amyloid Beta Interactions with Human Telomerase

Wang, J., Zhao, C., Zhao, A., Li, M., Ren, J., & Qu, X. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511030s · Cited by 90 · see citing works

A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)

Horrigan, J. P., Gomes, T. M. B., Snape, M., Nikolenko, N., McMorn, A., Evans, S., Yaroshinsky, A., Pasqua, O. E. D., Oosterholt, S. P., & Lochmüller, H. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.08.001 · Cited by 89 · see citing works

Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin

Bidon‐Chanal, A., Fuertes, A., Alonso, D. A., Pérez, D. I., Martı́nez, A., Luque, F. J., & Medina, M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.014 · Cited by 73 · see citing works

Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?

Simone, A. D., & Milelli, A. (2019) · ChemMedChem · doi:10.1002/cmdc.201900174 · Cited by 72 · see citing works

Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments.

Inestrosa, N., Alvarez, A. R., & Calderón, F. H. (1996) · PubMed · Cited by 71 · see citing works

Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review

Xu, M., Wang, S. L., Zhu, L., Wu, P., Dai, W., & Rakesh, K. P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.073 · Cited by 71 · see citing works

BACE inhibitor bust in Alzheimer trial

Mullard, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.43 · Cited by 70 · see citing works

3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer’s Disease

Prati, F., Simone, A. D., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Bertozzi, S. M., Pérez, D. I., Andrisano, V., Pérez‐Castillo, A., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00121 · Cited by 68 · see citing works

Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3

Oukoloff, K., Coquelle, N., Bartolini, M., Naldi, M., Guével, R. L., Bach, S., Josselin, B., Ruchaud, S., Catto, M., Pisani, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.063 · Cited by 66 · see citing works

The role of GSK3beta in the development of the central nervous system

Luo, J. (2012) · Frontiers in Biology · doi:10.1007/s11515-012-1222-2 · Cited by 65 · see citing works

Modulation of GSK-3β/β-Catenin Signaling Contributes to Learning and Memory Impairment in a Rat Model of Depression

Hui, J., Zhang, J., Pu, M., Zhou, X., Dong, L., Mao, X., Shi, G., Zou, J., Wu, J., Jiang, D., et al. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy040 · Cited by 60 · see citing works

Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer’s Disease

Simone, A. D., Pietra, V. L., Betari, N., Petragnani, N., Conte, M., Daniele, S., Pietrobono, D., Martini, C., Petralla, S., Casadei, R., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00507 · Cited by 58 · see citing works

Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease

Shi, X., Wu, J., Liu, P., & Liu, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.001 · Cited by 55 · see citing works

Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold

Wang, C. K. L., Northfield, S. E., Huang, Y., Ramos, M. C., & Craik, D. J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.006 · Cited by 52 · see citing works

Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§

Milelli, A., Simone, A. D., Ticchi, N., et al. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170309123920 · Cited by 52 · see citing works

Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors

Arfeen, M., Bhagat, S., Patel, R. V., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.075 · Cited by 49 · see citing works

First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents

Brogi, S., Ramunno, A., Savi, L., Chemi, G., Alfano, G., Pecorelli, A., Pambianchi, E., Galatello, P., Compagnoni, G., Focher, F., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.017 · Cited by 45 · see citing works

Cost of Treatment and Care for People with Alzheimer’s Disease: A Meta- Analysis

Marešová, P., Dolejš, J., Mohelská, H., & Bryan, L. L. K. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200102144640 · Cited by 45 · see citing works

Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies

Ballatore, C., Brunden, K. R., Trojanowski, J. Q., Lee, V. M. Y., Smith, A. B., & Huryn, D. M. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611794072605 · Cited by 44 · see citing works

Modeling of Tau-Mediated Synaptic and Neuronal Degeneration in Alzheimer's Disease

Jaworski, T., Kügler, S., & LEUVEN, F. V. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/573138 · Cited by 42 · see citing works

DAPK1: a Novel Pathology and Treatment Target for Alzheimer’s Disease

Xu, L.-Z., Li, B.-Q., & Jia, J.-P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1242-2 · Cited by 42 · see citing works

Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3α and β isoforms in patients with NIDDM

Hansen, L., Arden, K. C., Rasmussen, S., Viars, C. S., Vestergaard, H., Hansen, T. F., Møller, A. M., Woodgett, J. R., & Pedersen, O. B. (1997) · Diabetologia · doi:10.1007/s001250050771 · Cited by 39 · see citing works

Advances in tetrahydropyrido[1,2- a ]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors

Boulahjar, R., Ouach, A., Bourg, S., Bonnet, P., Lozach, O., Meijer, L., Guguen‐Guillouzo, C., Guével, R. L., Lazar, S., Mohamed Akssira, A., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.046 · Cited by 35 · see citing works

Glycogen synthase kinase‐3 and alternative splicing

Liu, X., & Klein, P. S. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1501 · Cited by 35 · see citing works

Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies

Butini, S., Gemma, S., Brindisi, M., Borrelli, G., Lossani, A., Ponte, A. M., Torti, A., Maga, G., Marinelli, L., Pietra, V. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101438u · Cited by 30 · see citing works

Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake

Zhang, P., Li, S., Gao, Y., Lu, W., Huang, K., Ye, D., Li, X., & Chu, Y. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.078 · Cited by 30 · see citing works

Recent Advances in Designing Substrate-Competitive Protein Kinase Inhibitors

Han, K.-C., Kim, S. Y., & Yang, E. G. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672697 · Cited by 14 · see citing works

“It Ain’t Over ’til It’s Over”a—The Search for Treatments and Cures for Alzheimer’s Disease

Hargreaves, R. J. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300359g · Cited by 14 · see citing works

Modulation of tau pathology in tau transgenic models

Brion, J., Ando, K., Héraud, C., & Leroy, K. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380996 · Cited by 11 · see citing works

Site‐directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non‐Nucleoside Inhibitors

Savi, L., Brindisi, M., Alfano, G., et al. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12630 · Cited by 7 · see citing works

Glycogen Synthase Kinase-3 Beta

National Cancer Institute (2020) · Definitions · doi:10.32388/84ie1d · Cited by 7 · see citing works

Challenges and hopes for Alzheimer’s disease

Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291 · see citing works

Multi-target neuroprotective effects of herbal medicines for Alzheimer's disease

Fernandes, F., Barroso, M. F., De Simone, A., Emriková, E., Dias-Teixeira, M., Pereira, J. P., Chlebek, J., Fernandes, V. C., Rodrigues, F., Andrisano, V., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115107 · Cited by 45 · see citing works

Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3β inhibitors for the treatment of Alzheimer's disease

Dong, Y., Lu, J., Zhang, S., Chen, L., Wen, J., Wang, F., Mao, Y., Li, L., Zhang, J., Liao, S., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106446 · Cited by 28 · see citing works

PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures

Coulon, A., Rabiller, F., Takalo, M., Roy, A., Pelletier, A., Martiskainen, H., Siedlecki-Wullich, D., Lannette-Weimann, N., Majerníková, N., Grenon, A., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02709-5 · Cited by 1 · see citing works

GSK3B wt Allele

National Cancer Institute (2020) · Definitions · doi:10.32388/jn7r58

In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3

Gould, T. D., Chen, G. J., & Manji, H. K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300283 · Cited by 217 · see citing works

[The role of glycogen synthase kinase-3 beta in the pathogenesis of liver ischemia reperfusion injury].

Ren, F., Zhang, H., Piao, Z.-F., et al. (2011) · PubMed · doi:10.3760/cma.j.issn.1007-3418.2011.07.018

GSK‐3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β‐catenin stabilisation without elevation of glycogen synthase activity

Culbert, A. A., Brown, M. J. B., Frame, S., Hagen, T., Cross, D. A. E., Bax, B. D., & Reith, A. D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02990-8 · Cited by 85 · see citing works

Glycogen synthase kinase 3: more than a namesake

Rayasam, G. V., Tulasi, V. K., Sodhi, R., Davis, J. A., & Ray, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00085.x · Cited by 485 · see citing works